和铂医药宣布与阿斯利康深化推进全球战略合作
HBM HOLDINGSHBM HOLDINGS(HK:02142) Xin Lang Cai Jing·2025-11-24 02:28

Core Viewpoint - Heptagon Pharmaceuticals (02142.HK) announced an update and deepening of its global strategic collaboration with AstraZeneca established in March 2025, focusing on the discovery and development of next-generation biotherapies, including antibody-drug conjugates (ADC) and T-cell engagers (TCE) [1] Group 1 - The collaboration will leverage the expertise of both companies in their respective fields [1] - AstraZeneca will nominate research projects to Heptagon Pharmaceuticals annually for the next four years, with the option to license these projects [1]